Cambridge, UK, 27th March 2021

TRx Biosciences is pleased to announce the first IP filing in relation to its novel oral drug delivery platform, which offers a radical approach to drug absorption, transport and tissue targeting.

TRx’s technology platform represents a paradigm shift in the way that oral drug uptake is considered with relevance across multiple therapeutic themes.
‍

TRx CEO, Dr Robin Bannister said:

“Recent breakthroughs in our research have made the TRx technology platform applicable to a broad range of small molecule drugs for the first time. In-vivo data is demonstrating exactly what we expected – that we can start to consider previously unexploited uptake channels as a novel route to maximising the therapeutic potential of many small molecules as new medicines.”